Location History:
- Santa Clara, CA (US) (2019 - 2021)
- Foster City, CA (US) (2023)
Company Filing History:
Years Active: 2019-2023
Title: Jiping Zha: Innovator in Antibody Development
Introduction
Jiping Zha is a notable inventor based in Santa Clara, California, recognized for his contributions to the field of biotechnology. With a total of six patents to his name, he has made significant strides in the development of therapeutic antibodies. His work focuses on targeting immune checkpoints to enhance cancer treatment options.
Latest Patents
Among his latest innovations are two groundbreaking patents related to antibodies. The first patent involves Anti PD-L1 antibodies, which are designed to bind to PD-L1, an important protein that inhibits immune responses. This invention presents humanized anti-PD-L1 antibodies and outlines methods for their application in clinical settings. The second patent pertains to Anti PD-1 antibodies, focusing on antibodies that bind to PD-1, another crucial immune checkpoint. Similar to the previous patent, it includes humanized anti-PD-1 antibodies and their methods of use, which could potentially lead to impactful advancements in immunotherapy.
Career Highlights
Jiping Zha has had an impressive career, collaborating with innovative companies such as Apollomics Inc. and Cb Therapeutics, Inc. These companies are known for their commitment to discovering and developing new therapeutic solutions in oncology and immunotherapy, making them ideal partners for Zha’s pioneering work.
Collaborations
Throughout his career, Jiping Zha has worked closely with talented individuals in the field. Notable coworkers include Junzhuan Qiu and Ziyong Sun. Their collaborative efforts have contributed to the advancement of antibody therapeutics, reinforcing the importance of teamwork in scientific innovation.
Conclusion
With a solid portfolio of patents and key collaborations in the biotech industry, Jiping Zha continues to lead the way in the development of antibody treatments. His innovative mindset and expertise in this specialized field promise to make significant contributions to cancer therapy and patient care in the future.